SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RAJU EASON who wrote ()11/15/1997 11:13:00 AM
From: VultureInvest   of 670
 
As an undertaker, a stock falling from $5 to around $1 is prime
for a rebound, especially with ramp-up, albeit slowly, in sales
and heavy cash still left to remain a going concern for
several years.

Part of their strategy is to conduct contract drug manufacturing with their plant. This looks like the brightest light in their dark tunnel. Think about all the startup medical companies needing to ramp-up on an FDA approved drugs. Either they are bought out by the big boys (i.e,
Merck, UpJohn, etc.) or they team with players who have the
manufacturing capacity, like Procyte. This is a company that offers
limited down-side, yet tremendous upside. Procyte will succeed
Forget about the oldman dumping his ownership. It is time to flow with the new blood which I see has strong strategic vision to achieve
a classic turnaround.

Best Investing
The Vulture
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News